Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

Publisher Website
Google Scholar
Abstract
In a recent issue of Blood we reported that rituximab anti-CD20 monoclonal antibody is an active drug in adults with chronic idiopathic thrombocytopenic purpura (ITP), that it is able to induce long-lasting responses, and that in all responders a rise of the platelet count occurs early during